Trials / Completed
CompletedNCT02674009
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
Non-Interventional Study to Investigate the Effectiveness, Safety and Utilization of Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions (NIELS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 67 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose for this multi-center, non-interventional study is to evaluate the duration of response defined as duration from first documented response of complete response (CR) or partial response (PR) until disease progression (as determined by the treating physician) for participants with laBCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vismodegib | Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling. |
Timeline
- Start date
- 2015-09-17
- Primary completion
- 2019-03-31
- Completion
- 2019-03-31
- First posted
- 2016-02-04
- Last updated
- 2019-05-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02674009. Inclusion in this directory is not an endorsement.